请使用支持JavaScript的浏览器! CellGenix/CellGenix® rh IL-4/1 mg/1003-1000_蚂蚁淘,【正品极速】生物医学科研用品轻松购|ebiomall 蚂蚁淘商城
商品信息
联系客服
CellGenix/CellGenix® rh IL-4/1 mg/1003-1000
郑重提醒:
无质量问题不接受退换货,下单前请仔细核对信息。
下单后请及时联系客服核对商品价格,订单生效后再付款。
CellGenix/CellGenix® rh IL-4/1 mg/1003-1000
品牌 / 
CellGenix
货号 / 
1003-1000
美元价:
(友情提示:该价格仅为参考,欢迎联系客服询价!)
数    量:
免费咨询热线
4000-520-616

Technical Details

Source
Expressed in E. coli
Description

Human Interleukin-4, accession # P05112, His25-Ser153

Formulation

Lyophilized from a 0.2 µm-filtered solution containing 1.5 mM potassium phosphate, 8.1 mM sodium phosphate, 2.7 mM potassium chloride and 137 mM sodium chloride, pH 7.5

Both product grades are produced under the same conditions in a GMP facility, ensuring an equal product quality and performance. We offer a more comprehensive QC testing including tighter specifications and documentation for our GMP products: Preclinical vs GMP.

 PreclinicalGMP
Molecular weight15.1 kDa15.1 kDa
Purity≥ 95% as determined by SDS-PAGE≥ 97% as determined by SDS-PAGE
Activity≥ 6 x 106 IU/mg, calibrated against NIBSC #88/656 Measured in a cell proliferation assay using an IL-4-dependent cell line, TF18 – 14 x 106 IU/mg, calibrated against NIBSC #88/656 Measured in a cell proliferation assay using an IL-4-dependent cell line, TF1

Batch specific activity on CoA

Endotoxin level< 1000 EU/mg≤ 50 EU/mg
Intended useIntended for preclinical ex vivo use. Not intended for therapeutic use.Intended for clinical ex vivo use. Not intended for human in vivo application.

Handling Instructions

Reconstitution

Recommended in sterile water to a final concentration of 250 µg/ml for 50 µg vials or 500 µg/ml for 1 mg vials.

Shipment

Ambient temperature. Please refer to Technote to learn more about our shipment validation procedure.

Expiry

≥ 6 months from date of shipping. Please refer to Certificate of Analysis for the exact expiry date.

Storage & Stability

Store lyophilized cytokine at -20°C to -80°C.

Store a 250 µg/ml reconstituted cytokine solution:

• 4 weeks at 2°C to 8°C under sterile conditions after reconstitution. Store in the original container. 

• 4 months at -20°C to -80°C under sterile conditions after reconstitution. Store in 60 µl aliquots in polypropylene cryogenic vials.

Avoid repeated freeze/thaw cycles.

Documents

  • Data Sheet: GMP or Preclinical
  • Material Safety Data Sheet: MSDS
  • Certificate of Analysis
  • Technote: ADCF and Serum-free Policy
  • Technote: Batch-to-Batch Consistency of CellGenix® GMP Cytokines
  • Technote: Stability of CellGenix® GMP Cytokines after Reconstitution
  • Technote: Shipment of CellGenix® Preclinical and GMP Cytokines at Ambient Temperatures
  • Technote: CellGenix® rh Cytokines - Preclinical vs GMP
  • More information under Resources

Data

CellGenix GMP rh IL-4 has an activity of 8 – 14 × 106 IU/mg

The activity of GMP rh IL-4 was measured in a cell proliferation assay using the IL-4-dependent cell line TF1. It was calibrated against NIBSC #88/656.

You can find the batch specific activity on the certificate of analysis (CoA).

Regulatory Support

We offer the following to assist you with your regulatory approval process:

  • Comprehensive documentation (e.g. DMFs, Regulatory Support Files, Certificates of Origin)
  • Outstanding QC support (e.g. extensive stability data)
  • The possibility to audit our production site
  • Detailed batch specific test results on our Certificates of Analysis
  • Change notifications prior to relevant changes

Customized solutions can be provided to meet special compliance needs. Contact our Regulatory Support Team for all your regulatory requests & questions:

Phone:     +49 761 88 88 9-302 Email:      regulatorysupport@cellgenix.com

In order to stay up-to-date and help improve regulatory guidance we are actively involved in many of the regulatory initiatives and discussions. We were amongst others actively involved in the discussions for the setup of Ph. Eur. General Chapter 5.2.12 and the ISO Technical Standard 20399.

Regulatory Resources

  • TSE certificate (available on request)
  • Regulatory Support File (available on request)
  • Request a DMF Letter of Authorization (USA only)

Publications

  • The importance of material selection in the differentiation of monocytes into dendritic cellsBoghosian et al., 2018, Cell & Gene Therapy Insights
  • Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritisBell, GM. Et al., 2017, Annals of the Rheumatic Diseases
  • Autocrine CCL19 blocks dendritic cell migration toward weak gradients of CCL21Hansen, M. et al., 2016, Cytotherapy
  • Tumor antigen–specific T cells for immune monitoring of dendritic cell–treated glioblastoma patientsMüller, I. et al., 2016, Cytotherapy
  • Survivin and PSMA Loaded Dendritic Cell Vaccine for the Treatment of Prostate CancerXi, HB. et al., 2015, Biological & Pharmaceutical Bulletin
  • Necrotic cell-derived high mobility group box 1 attracts antigen-presenting cells but inhibits hepatocyte growth factor-mediated tropism of mesenchymal stem cells for apoptotic cell deathVogel, S. et al., 2015, Cell Death and Differentiation
  • NF-kB, p38 MAPK, ERK1/2, mTOR, STAT3 and increased glycolysis regulate stability of paricalcitol/dexamethasone-generated tolerogenic dendritic cells in the inflammatory environmentDá?ová, K. et al., 2015, Oncotarget
  • Generation of lentivirus-induced dendritic cells under GMP-compliant conditions for adaptive immune reconstitution against cytomegalovirus after stem cell transplantationSundarasetty, BS. et al., 2015, Journal of Translational Medicine
  • Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patientsGao, D. et al., 2014, PLoS One
  • A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanomaPoschke, I. et al., 2014, Cancer Immunology, Immunotherapy
  • Antigen-specific activation and cytokine-faciliated expansion of naive, human CD8+ T cellsWölfl, M., Greenberg, PD., 2014, Nature Protocols
  • TLR4-mediated pro-inflammatory dendritic cell differentiation in humans requires the combined action of MyD88 and TRIFKolanowski, ST. et al., 2014, Innate Immunity
  • Inhibition of TNF receptor signaling by anti-TNF-a biologicals primes naive CD4+ T cells towards IL-10+ T cells with a regulatory phenotype and functionBooks, MA. et al., 2014, Clinical Immunology
  • In-chip fabrication of free-form 3D constructs for directed cell migration analysisOlsen, MH. et al., 2013, Lab on a Chip
  • The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysatesPellegatta, S. et al., 2013, Oncoimmunology
  • Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapyHansen, M. et al., 2013, Vaccine
  • Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancerIclozan, C. et al., 2013, Cancer Immunology, Immunotherapy
  • Melanoma immunotherapy using mature DCs expressing the constitutive proteasomeDanull, J. et al., 2013, The Journal of Clinical Investigation
  • Crosstalk between Toll like receptors and C5a receptor in human monocyte derived DCs suppress inflammatory cytokine produtionZaal, A. et al., 2013, Immunobiology
  • Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patientsRidolfi, L. et al., 2013, Journal of Translational Medicine
  • The macrophage mannose receptor promotes uptake of ADAMTS13 by dendritic cellsSorvillo, N. et al., 2012, Blood
  • Myeloid-derived suppressor cells impair the quality of dendritic cell vaccinesPoschke, I. et al., 2012, Cancer Immunology, Immunotherapy
  • Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A miceWroblewska, A. et al., 2012, Blood
  • Is Anticancer Vaccine Possible: Experimental Application of Produced mRNA Transfected Dendritic Cells Derived from Enriched CD34+ Blood Progenitor CellsLazarova, P. et al., 2012, Immunodeficiency, Chapter 3
  • Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapyVopenkova, K. et al., 2012, Journal of Cellular and Molecular Medicine
  • Identitiy, potency in vivo viability, and scaling up production of lentiviral vector-induced dendritic cells for melanoma immunotherapyPincha, M. et al., 2012, Human Gene Therapy Methods
  • An optimized method for manufacturing a clinical scale dendritic cell-based vaccine for the treatment of glioblastomaNava, S. et al., 2012, PloS One
  • A phase II study evaluating the safety and efficacy of an adenovirus-DLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinomaChia, WK. et al., 2012, Annals of Oncology
  • Cryopreservation of adenovirus-transfected dendritic cells (DCs) for clinical useGülen, D. et al., 2012, International Immunopharmacology
  • IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction – a comparative study of human clinical-applicable DCBoks, MA. et al., 2012, Clinical Immunology
  • HLA-DR-presented peptide-repertoires derived from human monocyte-derived dendritic cells pulsed with blood coagulation factor VIIIvan Haren, SD. et al., 2011, Molecular & Cellular Proteomics
  • Heat-shock protein 70-dependent dendritic cell activation by 5-aminolevulinic acid-mediated photodynamic treatment of human glioblastoma spheroids in vitroEtminan, N. et al., 2011, British Journal of Cancer
  • Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolizationNakamato, Y. et al., 2011, Clinical and Experimental Immunology
  • Antigen-Specific B Cells Reactivate an Effective Cytotoxic T Cell Response against Phagocytosed Salmonella through Cross-Presentationde Wit, J. et al., 2010, PLoS One
  • Tumor endothelial marker 8 expression levels in dendritic cell-based cancer vaccines are related to clinical outcomeVenanzi, FM. et al., 2010, Cancer, Immunology, Immunotherapy
  • A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oyaliplatin/capecitabine chemotherapy in colon cancer patientsLesterhuis, WJ. et al., 2010, British Journal of Cancer
  • Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis)Ridolfi, L. et al., 2010, Clinical and Developmental Immunology
  • Immune suppression by gammadelta T-cells as a potential regulatory mechanism after cancer vaccination with IL-12 secreting dendritic cellsTraxlmayr, MW. et al., 2010, Journal of Immunotherapy
  • Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patientsLesterhuis, WJ. et al., 2010, Anticancer Research
  • Dendritic cell-based vaccination of patients with advanced melanoma: update of clinical outcomeRidolfi, L. et al., 2010, Clinical and Developmental Immunology
  • Autologous dendritic cell vaccine for chronic hepatitis B carriers: a pilot, open label, clinical trial in human volunteersLuo, J. et al., 2010, Vaccine
  • Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trialTrepiakas, R. et al., 2010, Cytotherapy
  • CD40 ligand-triggered human dendritic cells mount interleukin-23 responses that are further enhanced by danger signalsSender, LY. et al., 2010, Molecular Immunology
  • Monophosphoryl lipid A plus IFN gamma maturation of dendritic cells induces antigen-specific CD8+ cytotoxic cells with high cytolytic potentialten Brinke, A. et al., 2010, Cancer Immunology, Immunotherapy
  • Development of a potency assay for human dendritic cells: IL-12p70 productionButterfield, LH. et al., 2008, Journal of Immunotherapy
蚂蚁淘电商平台
ebiomall.com
公司介绍
公司简介
蚂蚁淘(www.ebiomall.cn)是中国大陆目前唯一的生物医疗科研用品B2B跨境交易平台, 该平台由多位经验丰富的生物人和IT人负责运营。蚂蚁淘B2B模式是指客户有采购意向后在蚂蚁 淘搜索全球供应信息,找到合适的产品后在蚂蚁淘下单,然后蚂蚁淘的海外买手进行跨境采购、 运输到中国口岸,最后由蚂蚁淘国内团队报关运输给客户...
蚂蚁淘承诺
正品保证: 全球直采 在线追溯 蚂蚁淘所有产品都是自运营的,我们已经跟国外多家厂方建立品牌推广合作关系, 获得对方的支持和授权; 同时客户可以通过订单详情查看到货物从厂方至客户的所有流程, 确保货物的来源; 正规报关,提供13%增值税发票。
及时交付: 限时必达 畅选无忧 蚂蚁淘的运营团队都是有着多年经验的成员,他们熟悉海外采购、仓储物流、报关等环节; 同时通过在线的流程监控,蚂蚁淘的进口速度比传统企业提高了50%以上, 部分产品甚至能做到7-10天到货,即蚂蚁淘的“时必达”服务。
轻松采购: 在线下单 简单省事 蚂蚁淘的价格是真实透明的,并且具有很大的价格优势,不需要繁杂的询价比价; 报价单与合同可以直接在线生成或打印;就像在京东购物一样, 您的鼠标点击几 次即完成在蚂蚁淘的采购,订单详情会告诉您所有进程。
售后申请: 耐心讲解 优质服务 蚂蚁淘提供的产品在使用过程中如因产品质量问题有售后需求时, 您可通过我的订单提交您的“申请售后”, 蚂蚁淘产品顾问会第一时间为您处理, 在售后服务过程中如遇到问题也可致电蚂蚁淘客服热线:4000-520-616。
上海笃玛生物科技有限公司在发布的乙酸-EDTA缓冲液(pH5.5)供应信息,浏览与乙酸-EDTA缓冲液(pH5.5)相关的产品或在搜索更多与乙酸-EDTA缓冲液(pH5.5)相关的内容。 查看更多>
上海研生实业有限公司所提供的pH7.2 磷酸盐缓冲液质量可靠、规格齐全,上海研生实业有限公司不仅具有精湛的技术水平,更有良好的售后服务和优质的解决方案,欢迎您来电咨询此产品具体参数及价格等详细信息! 查看更多>
杆状病毒储液制备实验的相关实验步骤、实验技巧、实验protocol、实验经验及常见问题。&lt;link rel=&quot;stylesheet&quot; type=&quot;text/css&quot; href=&quot;/ueditor/themes/ifram... 查看更多>
可能原因 建 议 1、抗体浓度太高 一抗或二抗浓度太高会导致高背景,降低抗体浓度 2、使用的封闭液不兼容 对比不同的封闭缓冲液 3、非特异性位点封闭不足 优化封闭缓冲液,最好的封闭缓冲液具有系统依赖性 提高封闭液中蛋白的浓度 优化封闭时间和/或温度。室温封闭至少1 h或者4°C封闭过夜 在封闭液 查看更多>
上海哈灵生物科技有限公司在发布的PBS-EDTA缓冲液供应信息,浏览与PBS-EDTA缓冲液相关的产品或在搜索更多与PBS-EDTA缓冲液相关的内容。 查看更多>
最佳答案: (1)鸡蛋清中含有丰富的蛋白质.(2)由图表数据可以知道:酶E的最适pH为2左右,该实验的目的是:研究pH对酶E催化作用的影响.(3)根据实验,你对酶E能得出... 查看更多>
上海联硕生物科技有限公司在发布的氨-氯化铵缓冲液(pH10)供应信息,浏览与氨-氯化铵缓冲液(pH10)相关的产品或在搜索更多与氨-氯化铵缓冲液(pH10)相关的内容。 查看更多>
细胞培养的新手问题大全 查看更多>
规格(核心参数):1袋(可配250ml溶液);PH4.00;是PH计/酸度计上面用的试剂,也叫标准缓冲溶液、PH标准液/校准液 查看更多>
杆状病毒储液制备实验的相关实验步骤、实验技巧、实验protocol、实验经验及常见问题。&lt;link rel=&quot;stylesheet&quot; type=&quot;text/css&quot; href=&quot;/ueditor/themes/ifram... 查看更多>
Hippocampal Neuron Cultures (and mixed cortical cultures)Submitted by: Jean Siao, Ph.D.Begin by timing the pregnant mouse at E17-E19 days of gestation. Have re 查看更多>
上海远慕生物科技公司是国内elisa试剂盒优质供应商,代理销售不同elisa试剂盒品牌的进口/国产elisa试剂盒,专业供应科研实验所需的培养基,抗体,动物血清血浆,标准品对照品,化学试剂,酶联免疫试剂盒,白介素试剂盒,金标检测试剂盒,微生物,蛋白质,ELISA种属涵盖广,凭借多年行业经验,完善的售后服务,高质量的产品。欢迎来电咨询。 客户通过生物在线在上海远慕订购PBS磷酸缓冲液 中文名:PBS磷酸缓冲液 英... 查看更多>
常见问题
蚂蚁淘所售产品均为正品吗?
蚂蚁淘的创始人兼CEO是钟定松先生,具有十年的从业经验,在业界享有良好的口碑; Ebiomall是跨境直采平台,我们直接从厂家采购,自己的团队负责国际物流和清关,中间没有第三方,蚂蚁淘承诺所售产品仅为正品,假一罚十。
下单后可以修改订单吗?
未确认状态的订单可以修改,打开“订单详情”页面,点击右上角的“修改订单”即可,若已审核确定,则订单无法修改。
商品几天可以发货?
现货产品付款审核后即可发货,大部分期货产品在3周左右即可到货,提供时必达服务的产品订单审核十天内即可发货。
订单如何取消?
如订单处于未确定状态,进入“我的订单"页面,找到要取消的订单,点击“取消订单”按钮。
可以开发票吗?
本网站所售商品都是正规清关,均开具13%正规发票,发票金额含配送费金额,另有说明的除外。
如何联系商家?
蚂蚁淘任何页面都有在线咨询功能,点击“联系客服”、“咨询”或“在线咨询”按钮,均可咨询蚂蚁淘在线客服人员, 或拨打4000-520-616,除此之外客户可在 联系我们页面找到更多的联系方式。
收到的商品少了/发错了怎么办?
同个订单购买多个商品可能会分为一个以上包裹发出,可能不会同时送达,建议查看订单详情是否是部分发货状态;如未收到,可联系在线客服或者致电4000-520-616。
退换货/维修需要多长时间?
一般情况下,退货处理周期为客户收到产品一个月内(以快递公司显示签收时间为准),包装规格、数量、品种不符,外观毁损、短缺或缺陷,请在收到货24小时内申请退换货;特殊商品以合同条款为准。
商品咨询

我想问一下如何配置用于稀释病毒的PBS缓冲液

缓冲液;能抵御少量的酸,碱或稀释少量倍数时,体系的pH基本不变的溶液称为缓冲溶液.缓冲溶液的缓冲对一般是由共轭酸碱对或两性物质组成.缓冲对在生物中是指酸碱性相反的东西,,可以相互中和,比如在人体中,乳酸和碳酸氢钠就是一对缓冲对
求采纳为满意回答。

WB前,上样缓冲液是买的成品,在-20°冰箱保存,之前做一直正常,这次蛋白样品加上样缓冲液后变成棕色了?啥情况?是蛋白样品PH值的关系吗?这个还能继续跑电泳吗?

哪位高手给指导一下,谢谢!

由弱酸HA及其盐NaA所组成的缓冲溶液对酸的缓冲作用,是由于溶液中存在足够量的碱A-的缘故。当向这种溶液中加入一定量的强酸时,H+离子基本上被A-离子消耗,所以溶液的pH值几乎不变;当加入一定量强碱时,溶液中存在的弱酸HA消耗OH-离子而阻碍pH的变化。
  在缓冲溶液中加入少量强酸或强碱,其溶液pH值变化不大,但若加入酸,碱的量多时,缓冲溶液就失去了它的缓冲作用。这说明它的缓冲能力是有一定限度的。
  缓冲溶液的缓冲能力与组成缓冲溶液的组分浓度有关。0.1mol·L-1HAc和0.1mol· L-1NaAc组成的缓冲溶液,比0.01mol·L-1HAc和0.01mol·L-1NaAc的缓冲溶液缓冲能力大。关于这一点通过计算便可证实。但缓冲溶液组分的浓度不能太大,否则,不能忽视离子间的作用。
  组成缓冲溶液的两组分的比值不为1∶1时,缓冲作用减小,缓冲能力降低,当c(盐)/c(酸)为1∶1时△pH最小,缓冲能力大。不论对于酸或碱都有较大的缓冲作用。缓冲溶液的pH值可用下式计算:
  此时缓冲能力大。缓冲组分的比值离1∶1愈远,缓冲能力愈小,甚至不能起缓冲作用。对于任何缓冲体系,存在有效缓冲范围,这个范围大致在pKaφ(或pKbφ)两侧各一个pH单位之内。
  弱酸及其盐(弱酸及其共轭碱)体系pH=pKaφ±1
  弱碱及其盐(弱碱及其共轭酸)体系pOH=pKbφ±1
  例如HAc的pKaφ为4.76,所以用HAc和NaAc适宜于配制pH为3.76~5.76的缓冲溶液,在这个范围内有较大的缓冲作用。配制pH=4.76的缓冲溶液时缓冲能力最大,此时(c(HAc)/c(NaAc)=1。

  制备

  为了配制一定pH的缓冲溶液,首先选定一个弱酸,它的pKaφ尽可能接近所需配制的缓冲溶液的pH值,然后计算酸与碱的浓度比,根据此浓度比便可配制所需缓冲溶液。
  以上主要以弱酸及其盐组成的缓冲溶液为例说明它的作用原理、pH计算和配制方法。对于弱碱及其盐组成的缓冲溶液可采用相同的方法。
  缓冲溶液在物质分离和成分分析等方面应用广泛,如鉴定Mg2+ 离子时,可用下面的反应:
  白色磷酸铵镁沉淀溶于酸,故反应需在碱性溶液中进行,但碱性太强,可能生成白色Mg(OH)2沉淀,所以反应的pH值需控制在一定范围内,因此利用NH3·H2O和NH4Cl组成的缓冲溶液,保持溶液的pH值条件下,进行上述反应。
  常用缓冲液配制
  枸橼酸-磷酸氢二钠
  甲液:取枸橼酸21g或无水枸橼酸19.2g,加水使溶解成1000ml,置冰箱内保存。
  乙液:取磷酸氢二钠71.63g,加水使溶解成1000ml。
  取上述甲液61.45ml与乙液38.55ml,混合,摇匀,即得。
  氨-氯化铵缓冲液
  取氯化铵1.07g,加水使溶解成100ml, 再加稀氨溶液(1→30)调节pH值至8.0,即得。
  氨-氯化铵缓冲液
  取氯化铵5.4g,加水20ml溶解后,加浓氨溶液35ml,再加水稀释至100ml,即得。
  醋酸-醋酸钠缓冲液
  取无水醋酸钠20g,加水300ml溶解后,加溴酚蓝指示液1ml及冰醋酸60~80ml,至溶液从蓝色转变为纯绿色,再加水稀释至1000ml,即得。
  醋酸-醋酸钠缓冲液
  取醋酸钠18g,加冰醋酸9.8ml,再加水稀释至1000ml,即得。
  醋酸-醋酸钠缓冲液
  取醋酸钠54.6g,加1mol/L醋酸溶液20ml溶解后,加水稀释至500ml,即得。
  醋酸-醋酸铵缓冲液
  取醋酸铵7.7g,加水50ml溶解后,加冰醋酸6ml与适量的水使成100ml,即得。
  醋酸-醋酸铵缓冲液
  取醋酸铵77g,加水约200ml使溶解,加冰醋酸57ml,再加水至1000ml,即得。
  醋酸-醋酸铵缓冲液
  取醋酸铵100g,加水300ml使溶解,加冰醋酸7ml,摇匀,即得。
  磷酸盐缓冲液
  取0.2mol/L磷酸二氢钾溶液250ml,加0.2mol/L氢氧化钠溶液118ml,用水稀释至1000ml,即得。

  当往某些溶液中加入一定量的酸和碱时,有阻碍溶液pH变化的作用,称为缓冲作用,这样的溶液叫做缓冲溶液。弱酸及其盐的混合溶液(如HOAc与NaOAc),弱碱及其盐的混合溶液(如NH3·H2O与NH4Cl)等都是缓冲溶液。

  参考资料:http://baike.baidu.com/view/901429.htm

像图中所示,我1%的羧基微球用EDC活化,离心后用50Mm、PH7.2的PB缓冲液悬浮,用超声波超声5分钟,然后就分层了,上层是微球。

稳定PH值,通入酸性或碱性物质时 都能使PH保持在一个可以接受的范围内.
碳酸氢钠溶液是一种co2缓冲液,当瓶内二氧化碳量减少时,碳酸氢钠溶液释放co2,反之吸收co2.因此它能保持瓶内二氧化碳量大致不变.

日本药典中0.1mol/L的磷酸缓冲液pH7.0是怎么配置的啊,求救!!!!

选择缓冲溶液的原则:
1、 缓冲溶液对反应物的测定没有干扰
2、缓冲组分的浓度为1:1
3、有足够的缓冲容量
4、缓冲溶液的PH应在所需范围内
5、组成缓冲溶液的弱碱PKB和弱酸PKA应接近或等于所需的POH值或PH值(PH+POH=14)
配制
只要知道缓冲对的PH值,和要配制的缓冲液的pH值(及要求的缓冲液总浓度),就能按公式计算[盐]和[酸]的量。这个算法涉及对数换算,较麻烦,前人为减少后人的计算麻烦,已为我们总结出pH值与缓冲液对离子用量的关系并列出了表格。只要我们知道要配制的缓冲液的pH,经查表便可计算出所用缓冲剂的比例和用量。例如配制500nmpH5.8浓度为0.1M磷酸缓冲液。
经查表知pH5.8浓度为0.2M Na2HPO48.0毫升,而0.2M Na2HPO492.0毫升。依此可推论出配制100ml0.1M的磷酸缓冲液需要0.1M Na2HPO48.0毫升,而0.1M Na2HPO4需要92.0毫升。
计算好后,按计算结果准确称好固态化学成分,放于烧杯中,加少量蒸馏水溶解,转移入50ml容量瓶,加蒸馏水至刻度,摇匀,就能得到所需的缓冲液。
各种缓冲溶液的配制,均按表格按比例混合,某些试剂,必须标定配成准确浓度才能进行,如醋酸、氢氧化钠等。另外,所有缓冲溶剂的配制计量都能从以上的算式准确获得。
TBS缓冲液 123
弘贝方弘2017-10-02
索莱宝的TBS缓冲液怎么样

TBST中含有Tris-Hcl,NaCl,Tween20这三种物质,是做WESTERNBLOT中常用的一种缓冲液

TBST缓冲液的配制

1000ml×TBST的配置

先称量NaCl40g,倒入烧杯中,加DDW蒸馏水400ml,再称量NaCl47.6g,倒入刚才的那个烧杯中(PS:由于NaCl的量太多,一次称量不方便,所以分两次称量,且易于溶解)。往烧杯中加入Tris—HCl缓冲液100ml,最后加(吐温20)5ml,转入1000ml容量瓶中,在定容,转移即可。

TBST缓冲液的应用:

1.主要用于免疫组化和原位杂交,酶联免疫等实验中,清洗免疫印。

2.迹膜;

注意事项:

1.TBST缓冲液,PH7.2-7.5;

2.颜色为无色透明液体;

3.为了您的安全和健康,请穿实验服并戴防护手套操作;


TE缓冲液(pH 8.0)配制方法 123
风记社六团mfj2017-09-28
10 mmol/LTris-HCl(pH 8.0)
  1 mmol/LEDTA(pH 8.0)
  因为含有以上两种物质,所以称为TE。
  配制分三步:
  1)1 M Tris-HCl (pH 8.0) 50 ml的配制:称取Tris碱6.06 g,加超纯水40 ml溶解,滴加浓HCl约2.1 ml调pH至8.0,定容至50 ml。
  2)0.5 M EDTA(pH 8.0)50 ml的配制:称取EDTA-Na2·2H2O 9.306 g,加超纯水35 ml,剧烈搅拌,用约1 g NaOH颗粒调pH至8.0,定容至50 ml。(EDTA二钠盐需加入NaOH将pH调至接近8.0时,才会溶解。)
  3)1×TE(10 mM Tris-HCl,pH 8.0;1 mM EDTA,pH 8.0)的配制:
  作用:
  TE缓冲液是弱碱性,对DNA的碱基有保护性,(DNA在它是的稳定性较好,不易破坏其完整性或产生开环及断裂),包括提取好的DNA也要放在TE缓冲液是保存. 10mMTris-Hcl,pH有7.47.68.0三种。
  EDTA调到8.0是为了更好溶解,其他只要调到相应pH就可以。Tris在7-8附近缓冲能力很强,所以加8.0的EDTA下去后,不会改变pH。
浓度为0.11mol/l及pH7.2的磷酸盐缓冲液怎么配制?